Related Experiment Video

Updated: Jun 30, 2026

Characterization of Cell Membrane Extensions and Studying Their Roles in Cancer Cell Adhesion Dynamics
08:11

Characterization of Cell Membrane Extensions and Studying Their Roles in Cancer Cell Adhesion Dynamics

Published on: March 26, 2018

Controlling cell surface dynamics and signaling: how CD82/KAI1 suppresses metastasis

C K Miranti1

  • 1Laboratory of Integrin Signaling, Van Andel Research Institute, 333 Bostwick Ave NE, Grand Rapids, MI 49503, United States. cindy.miranti@vai.org

Cellular Signalling
|September 30, 2008
PubMed

Insights

Loss of metastasis suppressor genes, like KAI1/CD82, promotes cancer spread. Understanding the molecular events behind CD82 loss is crucial for developing new cancer metastasis therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metastasis Research

Background:

  • Metastasis suppressor genes negatively regulate cancer metastasis.
  • The molecular mechanisms underlying the loss of these genes and subsequent tumor metastasis are not well understood.
  • KAI1/CD82, a tetraspanin family member, is implicated in various metastatic cancers, but its precise function and role in normal biology require further elucidation.

Purpose of the Study:

  • To review the molecular events associated with the loss of KAI1/CD82.
  • To explore the impact of CD82 loss on signaling pathways regulating metastasis.
  • To examine the relationship between CD82 and other metastasis suppressor genes.

Main Methods:

  • Literature review and synthesis of existing research on KAI1/CD82.
  • Analysis of molecular events linked to CD82 loss.
  • Investigation of signaling pathways affected by CD82.

Main Results:

  • The loss of KAI1/CD82 is linked to increased cancer metastasis.
  • CD82's function as a metastasis suppressor involves complex molecular events and signaling pathway alterations.
  • CD82 interacts with other metastasis suppressor genes, suggesting a coordinated role in controlling cancer spread.

Conclusions:

  • Further research into the molecular mechanisms of CD82 loss is essential for understanding and targeting cancer metastasis.
  • Elucidating CD82's role in normal biology and its interactions with other suppressors can reveal novel therapeutic strategies.
  • Targeting CD82 pathways may offer a promising approach to inhibit metastasis in various cancers.

More Related Videos

The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues07:39

The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues

Published on: June 16, 2018

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Related Concept Videos

Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Cell-surface Signaling01:21

Cell-surface Signaling

Hormones—or any molecule that binds to a receptor, known as a ligand—that are lipid-insoluble (water-soluble) are not able to diffuse across the cell membrane. In order to be able to affect a cell without entering it, these hormones bind to receptors on the cell membrane. When a first messenger, a hormone, binds to a receptor, a signal cascade is set off, causing second messengers, proteins inside the cell, to become activated, resulting in downstream effects.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...